MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jri.2026.104894

Медицинская библиотека · Journal of reproductive immunology · 2026

Oncofertility pharmacovigilance in women receiving immune checkpoint inhibitors: Reproductive risks, fertility preservation, and pregnancy outcomes.

Shi Jing, Han Dong-Lin, Jiang Han, Ge Yi-Meng, Liu Qiong, Zhang Jun, Zhang Xiao-Nan, Zhao Jie

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Immune checkpoint inhibitors (ICIs) are increasingly used across disease stages, including adjuvant, first-line metastatic, and later-line settings, leading to a growing population of women of reproductive age exposed to these agents. As survival improves, reproductive health considerations have become increasingly relevant. This review summarizes current evidence regarding reproductive risks associated with ICIs, fertility preservation (FP) strategies, and pregnancy outcomes following exposure. Preclinical studies suggest that PD-1/PD-L1 blockade may disrupt ovarian immune homeostasis, promote inflammatory cytokine activation, and accelerate primordial follicle depletion. However, clinical data remain limited, with no definitive evidence of consistent ovarian reserve decline or histologically confirmed follicular loss in humans. The potential impact of ICIs on oocyte quality, embryonic development, and ovarian tissue viability remains uncertain, reflecting a critical evidence gap between mechanistic and clinical data. FP strategies are categorized into embryo/oocyte cryopreservation and ovarian tissue cryopreservation, highlighting their distinct biological targets-developing oocytes versus dormant primordial follicles-and their differential susceptibility to immune-mediated injury. Key considerations include potential genotoxicity, reproductive and developmental toxicity, and the timing of FP relative to treatment line and disease stage. Available pharmacovigilance data on pregnancy during or after ICI exposure do not demonstrate a clear increase in congenital anomalies but suggest potential risks of immune-related obstetric complications. Given the expanding use of ICIs in curative-intent settings, early integration of reproductive counseling and individualized risk assessment is essential. Prospective registries and translational studies are urgently needed to define the true gonadotoxic and developmental risks of ICIs and to optimize fertility preservation strategies in this population.

Для цитирования: Shi Jing, Han Dong-Lin, Jiang Han, Ge Yi-Meng, Liu Qiong, Zhang Jun, Zhang Xiao-Nan, Zhao Jie. Oncofertility pharmacovigilance in women receiving immune checkpoint inhibitors: Reproductive risks, fertility preservation, and pregnancy outcomes.. Journal of reproductive immunology. 2026. DOI: 10.1016/j.jri.2026.104894.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.